<DOC>
	<DOC>NCT00216372</DOC>
	<brief_summary>The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.</brief_summary>
	<brief_title>Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>digestive obstruction located in the upper part of the gastrointestinal tract digestive obstruction of malignant origin peritoneal carcinomatosis confirmed by a CT Scan at least two vomiting episodes per day or a presence of a nasogastric suction tube inoperable patients specific anticancer therapy within the previous 15 days signs of bowel perforation somatostatin or any analogue as treatment of the bowel obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>carcinomatosis</keyword>
</DOC>